SCHEMBL4274813

SCHEMBL4274813

C=C(O)c1cccnc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9412699 0.86 ALDH1A1 (0.57)
SCHEMBL9412694 0.86 ALDH1A1 (0.57)
SCHEMBL29721526 0.86 ALDH1A1 (0.57)
SCHEMBL8865984 0.83 ALDH1A1 (0.58)
SCHEMBL708637 0.81
SCHEMBL24579551 0.80 ALDH1A1 (0.67)
SCHEMBL27812729 0.80
SCHEMBL10889914 0.80 ALDH1A1 (0.60)
SCHEMBL9477069 0.80 ALDH1A1 (0.60)
SCHEMBL609057 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020028684-A1 SALTS OF NICOTINIC ACID AND NICOTINAMIDE AS ANTI-AGING AGENTS Jumpstart Fertility Pty Ltd (AU) 2020-02-06 WO disclosed
US-9955693-B2 Method for controlling phytopathogenic filamentous fungi other than oomycete microorganisms NIPPON SODA CO., LTD. (JP) 2018-05-01 US disclosed
US-20180105498-A1 COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS NUSIRT SCIENCES, INC. 2018-04-19 US disclosed
EP-2965628-A1 METHOD FOR CONTROLLING PHYTOPATHOGENIC FILAMENTOUS FUNGI OTHER THAN OOMYCETE MICROORGANISMS Nippon Soda Co., Ltd. (JP) 2016-01-13 EP disclosed
US-20160000083-A1 METHOD FOR CONTROLLING PHYTOPATHOGENIC FILAMENTOUS FUNGI OTHER THAN OOMYCETE MICROORGANISMS NIPPON SODA CO., LTD. (JP) 2016-01-07 US disclosed
US-8003783-B2 Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer STERIX LIMITED (GB) 2011-08-23 US disclosed
US-8003783-B2 Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer STERIX LIMITED (GB) 2011-08-23 US disclosed
WO-2010005581-A1 NIACIN COMPOSITIONS FOR REDUCTION OF AMYLOID BETA PEPTIDE 42 (ABETA 42) PRODUCTION AND FOR TREATMENT OF ALZHEIMER'S DISEASE (AD) KAREUS THERAPEUTICS, LLC (US) 2010-01-14 WO disclosed
EP-2120585-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE Amphastar Pharmaceuticals Incorporation (US) 2009-11-25 EP disclosed
US-20090186900-A1 COMPOUND STERIX LIMITED (GB) 2009-07-23 US disclosed
US-20090186900-A1 COMPOUND STERIX LIMITED (GB) 2009-07-23 US disclosed
WO-2008151073-A1 COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-12-11 WO disclosed
WO-2008109179-A1 METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-09-12 WO disclosed
WO-2008085281-A1 LONG TERM SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING AQUEOUS SUSPENSION OF BISPHOSPHONATE AMPHASTAR PHARMACEUTICALS, INC. (US) 2008-07-17 WO disclosed
WO-2007096647-A2 DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER STERIX LIMITED (GB) 2007-08-30 WO disclosed
WO-2007036733-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed
EP-1117411-A1 PROCESS FOR THE PREPARATION OF ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING BIPHOSPHONATES F. HOFFMANN-LA ROCHE AG (CH) 2001-07-25 EP disclosed
EP-1117412-A1 COMPOSITIONS CONTAINING DIPHOSPHONIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2001-07-25 EP disclosed
WO-2000021541-A1 PROCESS FOR THE PREPARATION OF ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING BIPHOSPHONATES F. HOFFMANN-LA ROCHE AG (CH) 2000-04-20 WO disclosed
WO-2000021540-A1 COMPOSITIONS CONTAINING DIPHOSPHONIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2000-04-20 WO disclosed